Novel acquisitions on biology and management of transformed follicular lymphoma

Carla Minoia, Emanuele Zucca, Annarita Conconi

Research output: Contribution to journalReview articlepeer-review


Follicular lymphoma (FL) generally has an indolent clinical course, but in some patients, a histological transformation (HT) into aggressive entities may take place and often lead to a poorer survival. The rituximab era has seen an improved outcome of FL, including those with HT. The current treatment strategies for transformed FL are based on immunochemotherapy for the cases with HT at the time of diagnosis or as the first event after watchful waiting. Patients transforming after prior treatment of FL usually benefit from autologous stem cell transplant. Unfortunately, early assessment of the transformation risk remains elusive. Recent studies delved the mechanisms of HT, showing that this is a complex process, resulting from a number of epigenetic and genetic lesions occurring in the tumour cell population as well as progressive changes in the tumour microenvironment. This novel knowledge has prompted clinical investigations on a variety of new therapeutic strategies.

Original languageEnglish
Pages (from-to)617-623
Number of pages7
JournalHematological Oncology
Issue number4
Publication statusPublished - Oct 1 2018


  • biology
  • histological transformation
  • outcome
  • transformed follicular lymphoma
  • treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel acquisitions on biology and management of transformed follicular lymphoma'. Together they form a unique fingerprint.

Cite this